Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;17(12):62.
doi: 10.1007/s11864-016-0439-8.

Oligometastatic Prostate Cancer

Daniel J Stevens  1 , Prasanna Sooriakumaran  2
Affiliations
Review

Oligometastatic Prostate Cancer

Daniel J Stevens et al. Curr Treat Options Oncol. 2016 Dec.

Abstract

The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatment to their primary tumour alongside 'metastasis-directed therapy' to the metastatic deposits. However, this regimen should be reserved to high-volume centres with quality assurance programmes and excellent outcomes. Patients should be made clear as to the uncertainty of benefit for this multi-site treatment strategy, and we await the publication of randomised controlled trials reporting in the next 5 years.

Keywords: Oligometastatic; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Daniel J. Stevens and Prasanna Sooriakumaran declare that they have no conflict of interest. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

References and Recommended Reading

Papers of particular of interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. James N, Spears M, Clarke N, Dearnaley D, De Bono J, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: Data from 917 Patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67(6):1028–38. doi: 10.1016/j.eururo.2014.09.032. - DOI - PubMed
    1. Heijnsdijk E, de Carvalho T, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC Data. JNCI J Nat Cancer Inst. 2014;107(1):dju366. doi: 10.1093/jnci/dju366. - DOI - PMC - PubMed
    1. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes R, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63. doi: 10.1016/j.eururo.2014.09.004. - DOI - PubMed
    1. Khoo V. Is there another bite of the cherry? The case for radical local therapy for oligometastatic disease in prostate cancer. Eur Urol. 2016;69(1):13–4. doi: 10.1016/j.eururo.2015.07.073. - DOI - PubMed